As of November 10, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of Relmada Therapeutics, Inc. The largest reported stake is Janus Henderson Group Plc's, at 10.1%. 12 filings are on record since August 14, 2025 (Schedule 13G, February 6, 2026).
Sell to companies like Relmada Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Squadron Master Fund LP · Sole voting: 0 · Shared voting: 7,350,000 · Sole dispositive: 0 · Shared dispositive: 7,350,000 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: BlackRock, Inc. · Sole voting: 7,255,400 · Shared voting: 0 · Sole dispositive: 7,352,913 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-29
- · Reporting person: Millennium Management LLC · Sole voting: 0 · Shared voting: 4,567,952 · Sole dispositive: 0 · Shared dispositive: 4,567,952 · SCHEDULE 13G, 2026-06-22
- · Reporting person: Venrock Healthcare Capital Partners III, L.P. · Sole voting: 0 · Shared voting: 6,508,433 · Sole dispositive: 0 · Shared dispositive: 6,508,433 · SCHEDULE 13G, 2026-06-09
- · Holder: Adage Capital Management, L.P. · Percent: 4.54% · SCHEDULE 13G/A
Relmada Therapeutics, Inc. has 12 Schedule 13D or 13G filings on record since 2025-08-14. 6 holders' latest filing reports 5% or more of common stock, $0.001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Janus Henderson Group Plc | 10.1% | 7,439,415 | SCHEDULE 13G, 2026-02-06 | 2026-01-30 |
| Squadron Master Fund LP | 7% | 7,350,000 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| BlackRock, Inc. | 7% | 7,352,913 | SCHEDULE 13G, 2026-07-29 | 2026-06-30 |
| Venrock Healthcare Capital Partners III, L.P. | 6.2% | 6,508,433 | SCHEDULE 13G, 2026-06-09 | 2026-06-02 |
| Spruce Street Capital LP | 5.57% | 4,086,181 | SCHEDULE 13G, 2026-02-17 | 2025-12-31 |
| Commodore Capital LP | 5.1% | 5,505,527 | SCHEDULE 13G, 2026-05-04 | 2026-04-27 |
| Ikarian Capital, LLC | 4.8% | 3,543,359 | SCHEDULE 13G, 2025-11-14 | 2025-09-30 |
| Adage Capital Management, L.P. | 4.54% | 4,763,158 | SCHEDULE 13G/A, 2026-05-13 | 2026-03-31 |
| Millennium Management LLC | 4.4% | 4,567,952 | SCHEDULE 13G, 2026-06-22 | 2026-06-16 |
Holding shares or following this stake? See who's behind Relmada Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Relmada Therapeutics, Inc. and the records around it.
Relmada Therapeutics, Inc. elsewhere on the record
Companies that share a holder
- Spruce Street Capital LP also filed stake reports on 1 other company: Research Alliance Corp III (Aug 2026)
- Squadron Master Fund LP also filed stake reports on 14 other companies: Contineum Therapeutics, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026), C4 Therapeutics, Inc. (Aug 2026)
- Ikarian Capital, LLC also filed stake reports on 22 other companies: Quoin Pharmaceuticals Ltd. (Oct 2026), Connect Biopharma Holdings Limited (Aug 2026), Galera Therapeutics, Inc. (Aug 2026)
Watch Relmada Therapeutics, Inc.
Get an email when Relmada Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Relmada Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Relmada Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Relmada Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Squadron Master Fund LP | 0 | 7,350,000 | 0 | 7,350,000 | SCHEDULE 13G/A, 2026-08-14 |
| Squadron Capital Management LLC | 0 | 7,350,000 | 0 | 7,350,000 | SCHEDULE 13G/A, 2026-08-14 |
| Matthew Sesterhenn | 0 | 7,350,000 | 0 | 7,350,000 | SCHEDULE 13G/A, 2026-08-14 |
| William Blank | 0 | 7,350,000 | 0 | 7,350,000 | SCHEDULE 13G/A, 2026-08-14 |
| BlackRock, Inc. | 7,255,400 | 0 | 7,352,913 | 0 | SCHEDULE 13G, 2026-07-29 |
| Venrock Healthcare Capital Partners III, L.P. | 0 | 6,508,433 | 0 | 6,508,433 | SCHEDULE 13G, 2026-06-09 |
| VHCP Co-Investment Holdings III, LLC | 0 | 6,508,433 | 0 | 6,508,433 | SCHEDULE 13G, 2026-06-09 |
| Venrock Healthcare Capital Partners EG, L.P. | 0 | 6,508,433 | 0 | 6,508,433 | SCHEDULE 13G, 2026-06-09 |
| VHCP Management III, LLC | 0 | 6,508,433 | 0 | 6,508,433 | SCHEDULE 13G, 2026-06-09 |
| VHCP Management EG, LLC | 0 | 6,508,433 | 0 | 6,508,433 | SCHEDULE 13G, 2026-06-09 |
| Nimish Shah | 0 | 6,508,433 | 0 | 6,508,433 | SCHEDULE 13G, 2026-06-09 |
| Bong Y. Koh | 0 | 6,508,433 | 0 | 6,508,433 | SCHEDULE 13G, 2026-06-09 |
| Millennium Management LLC | 0 | 4,567,952 | 0 | 4,567,952 | SCHEDULE 13G, 2026-06-22 |
| Millennium Group Management LLC | 0 | 4,567,952 | 0 | 4,567,952 | SCHEDULE 13G, 2026-06-22 |
| Israel A. Englander | 0 | 4,567,952 | 0 | 4,567,952 | SCHEDULE 13G, 2026-06-22 |
The latest filing identifies Relmada Therapeutics, Inc. by CUSIP 75955J402 and gives its principal executive office as 2222 PONCE DE LEON BLVD., FLOOR 3, CORAL GABLES, FL 33134 (SCHEDULE 13G/A, 2026-08-14).
What the percentages are based on
Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the shares of common stock of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.Venrock Healthcare Capital Partners III, L.P., SCHEDULE 13G, 2026-06-09
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Squadron Capital Management LLC | 9.9% | SCHEDULE 13G/A |
| 2025-11-14 | Ikarian Capital, LLC | 4.8% | SCHEDULE 13G |
| 2026-02-06 | Janus Henderson Group Plc | 10.1% | SCHEDULE 13G |
| 2026-02-12 | Adage Capital Management, L.P. | 5.82% | SCHEDULE 13G |
| 2026-02-17 | Spruce Street Capital LP | 5.57% | SCHEDULE 13G |
| 2026-02-17 | Squadron Master Fund LP | 9.9% | SCHEDULE 13G/A |
| 2026-05-04 | Commodore Capital LP | 5.1% | SCHEDULE 13G |
| 2026-05-13 | Adage Capital Management, L.P. | 4.54% | SCHEDULE 13G/A |
| 2026-06-09 | Venrock Healthcare Capital Partners III, L.P. | 6.2% | SCHEDULE 13G |
| 2026-06-22 | Millennium Management LLC | 4.4% | SCHEDULE 13G |
| 2026-07-29 | BlackRock, Inc. | 7% | SCHEDULE 13G |
| 2026-08-14 | Squadron Master Fund LP | 7% | SCHEDULE 13G/A |
Questions about who owns Relmada Therapeutics, Inc.
Who owns Relmada Therapeutics, Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of Relmada Therapeutics, Inc.: Janus Henderson Group Plc (10.1%, Schedule 13G, filed 2026-02-06), Squadron Master Fund LP (7%, Schedule 13G/A, filed 2026-08-14), BlackRock, Inc. (7%, Schedule 13G, filed 2026-07-29), Venrock Healthcare Capital Partners III, L.P. (6.2%, Schedule 13G, filed 2026-06-09) and Spruce Street Capital LP (5.57%, Schedule 13G, filed 2026-02-17); 1 more is listed above.
Who are the largest shareholders of Relmada Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Relmada Therapeutics, Inc. on this page are Janus Henderson Group Plc (10.1%), Squadron Master Fund LP (7%) and BlackRock, Inc. (7%).
When did Janus Henderson Group Plc buy into Relmada Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Janus Henderson Group Plc on this page is the Schedule 13G, filed 2026-02-06, reporting 10.1%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Relmada Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.